Emalex Biosciences Acquired by Teva Pharmaceutical | Healthcare M&A Deal

Teva Pharmaceutical has acquired Emalex Biosciences, a healthcare services other business in the U.S., for $700 million. Emalex Biosciences is developing ecopipam, an experimental Tourette syndrome drug in late-stage clinical testing, targeting the D1 dopamine-regulating protein implicated in tics. Teva Pharmaceutical acquisitions aim to expand its neurology pipeline by adding a D1 mechanism that differs from standard D2-focused antipsychotics. The platform acquisition is a strategic acquisition and Teva will pay $700 million upfront with up to $200 million in performance-based milestones plus sales-based royalties. The deal is announced and expected to close between July and September 2026.